ProfileGDS5678 / 1416180_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 79% 81% 79% 78% 82% 79% 79% 80% 82% 83% 80% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5734380
GSM967853U87-EV human glioblastoma xenograft - Control 25.6052979
GSM967854U87-EV human glioblastoma xenograft - Control 35.873881
GSM967855U87-EV human glioblastoma xenograft - Control 45.6385479
GSM967856U87-EV human glioblastoma xenograft - Control 55.4177378
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7734782
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.393279
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4607179
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6741880
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0193282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0279683
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6821280
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4967979
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.697880